(2,2-dimethoxyethyl)-isopropyl-methyl-amine | 291771-05-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2,2-dimethoxyethyl)-isopropyl-methyl-amine
• 英文别名: N-(2,2-dimethoxyethyl)-N-methylpropan-2-amine
• CAS: 291771-05-6
• 化学式: C₈H₁₉NO₂
• 分子量: 161.244
• InChiKey: ZNEANJQKYVAVSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2,2-dimethoxyethyl)-isopropyl-methyl-amine 在 palladium on activated charcoal 4-二甲氨基吡啶 、 水 、 氢气 、 对甲苯磺酸 、 三乙胺 作用下， 以 甲醇 、 苯 为溶剂， 22.0~25.0 ℃ 、275.79 kPa 条件下， 反应 66.0h， 生成 4-(2-dicyclohexyl-acetoxymethyl)-2-(N-isopropyl-N-methyl-aminomethyl)-1,3-dioxolane
  参考文献：
  名称：

  Design, synthesis and binding at cloned muscarinic receptors of N -[5-(1′-substituted-acetoxymethyl)-3-oxadiazolyl] and N -[4-(1′-substituted-acetoxymethyl)-2-dioxolanyl] dialkyl amines

  摘要：

  Few muscarinic antagonists differentiate between the M-4 and M-2 muscarinic receptors. In a structure-activity study, aimed at discovering leads for the development of a M-4 muscarinic receptor-selective antagonist, we have synthesized and tested at cloned muscarinic receptors the binding of a group of dioxolane- or oxadiazole-dialkyl amines, and compared them to our compound 1, which contains the furan nucleus. Although none of these agents were particularly potent at M-4 receptors (K-d values were typically 30-70 nM), furan derivatives (-)1 and (+)1 were significantly more potent at M-4 receptors than at M-2 receptors (similar to 3- and 4-fold, respectively). The dioxolane derivatives 12b and 12c were more than 10-fold selective for the M-4 versus the M-2 receptors, while the dioxolane derivative 12e was 15-fold more potent at M-4 receptors than for M-2 receptors. However, these agents bound to M-3 receptors with potencies like that for the M-4 receptor, so they are not M-4-selective. The M-4/M-2 relative selectivities of some of our compounds are similar to the better hexahydrosiladifenidol derivatives, and may provide some important structural clues for the development of potent and selective M-4 antagonists. (C) 2000 Elsevier Science Ltd. Ail rights reserved.

  DOI：

  10.1016/s0968-0896(00)00092-4
• 作为产物：
  描述：

  N-异丙基甲胺 、 2-氯乙醛缩二甲醇 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以35%的产率得到(2,2-dimethoxyethyl)-isopropyl-methyl-amine
  参考文献：
  名称：

  Design, synthesis and binding at cloned muscarinic receptors of N -[5-(1′-substituted-acetoxymethyl)-3-oxadiazolyl] and N -[4-(1′-substituted-acetoxymethyl)-2-dioxolanyl] dialkyl amines

  摘要：

  Few muscarinic antagonists differentiate between the M-4 and M-2 muscarinic receptors. In a structure-activity study, aimed at discovering leads for the development of a M-4 muscarinic receptor-selective antagonist, we have synthesized and tested at cloned muscarinic receptors the binding of a group of dioxolane- or oxadiazole-dialkyl amines, and compared them to our compound 1, which contains the furan nucleus. Although none of these agents were particularly potent at M-4 receptors (K-d values were typically 30-70 nM), furan derivatives (-)1 and (+)1 were significantly more potent at M-4 receptors than at M-2 receptors (similar to 3- and 4-fold, respectively). The dioxolane derivatives 12b and 12c were more than 10-fold selective for the M-4 versus the M-2 receptors, while the dioxolane derivative 12e was 15-fold more potent at M-4 receptors than for M-2 receptors. However, these agents bound to M-3 receptors with potencies like that for the M-4 receptor, so they are not M-4-selective. The M-4/M-2 relative selectivities of some of our compounds are similar to the better hexahydrosiladifenidol derivatives, and may provide some important structural clues for the development of potent and selective M-4 antagonists. (C) 2000 Elsevier Science Ltd. Ail rights reserved.

  DOI：

  10.1016/s0968-0896(00)00092-4

文献信息

• Dihydropyrancarboxamides and uses thereof
  申请人：Schreiber L. Stuart

  公开号：US20080070916A1

  公开（公告）日：2008-03-20

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新型二氢吡嗪羧酰胺化合物以及这些化合物的集合，并提供了合成这些化合物的方法；其中R1-R6如本文所定义。此外，本发明还提供了治疗增生性疾病和癌症等疾病的药物组合物和方法。
• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。
• IDO INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160200674A1

  公开（公告）日：2016-07-14

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

  本发明揭示了一些化合物，可调节或抑制吲哚胺2,3-二氧化酶（IDO）的酶活性，包括含有该化合物的制药组合物，以及利用本发明中的化合物治疗增生性疾病（如癌症、病毒感染和/或自身免疫疾病）的方法。
• Amine-containing lipids and uses thereof
  申请人：Anderson Daniel G.

  公开号：US20110009641A1

  公开（公告）日：2011-01-13

  Nitrogen-containing lipids prepared from the conjugate addition of amines to acrylates, acrylamides, or other carbon-carbon double bonds conjugated to electron-withdrawing groups are described. Methods of preparing these lipids from commercially available starting materials are also provided. These amine-containing lipids or salts forms of these lipids are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these lipids, they are particularly suited for the delivery of polynucleotides. Complexes or nanoparticles containing the inventive lipid and polynucleotide have been prepared. The inventive lipids may also be used to in preparing microparticle for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
• US7186709B2
  申请人：——

  公开号：US7186709B2

  公开（公告）日：2007-03-06